We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 63.00 | 61.00 | 65.00 | 63.00 | 63.00 | 63.00 | 0.00 | 07:36:40 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -4.80 | 14.85M |
From Apr 2019 to Apr 2024
TIDMNSCI
RNS Number : 2777B
NetScientific PLC
03 April 2017
3 April 2016
NetScientific plc
("NetScientific" or the "Group")
NetScientific Full Year Results for the year ended 31 December 2016
London, UK - 3 April 2017 - NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, announces its audited full year results for the year ended 31 December 2016.
Operational highlights:
Portfolio progress:
-- Vortex BioSciences
o Gained CE Mark and FDA Class 1 Registration for its liquid biopsy VTX-1 system
o Studies presented at the American Association for Cancer Research (AACR) support the application of Vortex's VTX-1 product
o Leading advisors appointed to the Scientific Advisory Board led by Massimo Cristofanilli, M.D.
o Appointment of Deborah Neff, ex Chief Operating Officer of Complete Genomics, as Non-Executive Director
o Exclusive license of a series of four patents covering a novel cell electroporation technology from Harvard University
o Co-founder and Chief Scientific Advisor, Professor Dino Di Carlo, received the US Presidential Early Career Award for Scientists and Engineers, for devising a first-of-its-kind technique
-- Glycotest
o Medical Advisory Board formed, including leading experts in liver disease to advise on the development of diagnostic test for liver related diseases
o Strengthened its intellectual property portfolio with Japanese Patent grant
o HCC Panel clinical validation study plan developed, with investigators and sites identified
-- ProAxsis
o Successfully registered a CE Mark to enable commercialisation in laboratories of its respiratory test, a novel ProteaseTag(R) Active Neutrophil Elastase Immunoassay (NE), for chronic respiratory diseases including COPD and Cystic Fibrosis
o Established a leading Scientific Advisory Board to support the development of its ProteaseTag(R) activity-based immunoassays and point-of-care tests
o NE immunoassay highlighted as highly predictive for future respiratory exacerbations in University of Dundee publication (American Journal of Respiratory and Critical Care Medicine, December 2016)
o Company awarded research grants from BioMedical Catalyst, Invest Northern Ireland and Innovate UK
-- Wanda
o Foad Dabiri was appointed Chief Executive Officer, taking over from Steve Curd, to refocus Wanda on its core strategy and progress the Company through its commercialisation phase
o Formation of Scientific Advisory Board, including distinguished physicians, health economics scientists, and technologists
o Signed contract with Health Resource Solutions, enabling the organisation to use WANDA's chronic condition digital management platform to provide improved at home care to its patients
o Wanda selected by Los Angeles-based 24Hr HomeCare to provide its predictive analytics and behavioural guidance technology to improve outcomes for at risk-patients and reduce hospital readmissions
o Collaborative deal with one of the US's biggest hospital groups, Dignity Health, to launch OncoVerse, the first ever digital health oncology care platform
-- PDS Biotechnology
o Positive Phase I study results for its PDS0101 immunotherapy for HPV-related cancers and initiates planning for upcoming Phase II clinical trials in several HPV-related cancers
o Signed a Co-operative Research and Development Agreement with the National Cancer Institute, a division of the US National Institutes of Health, to co-develop novel cancer immunotherapies through Phase II clinical trials
o Appointed Dr Robert Shepard, M.D., F.A.C.P. as Chief Medical Officer and Dr Panna L. Dutta, Ph.D. as Vice President of Drug Development and Manufacturing
o NetScientific converts warrants and loan to increase shareholding from 14.85% to 17.4%
Corporate highlights:
-- Appointment of Ian Postlethwaite as Chief Financial Officer -- Professor Stephen Smith joined the Board as Non-Executive Director of NetScientific
Financial highlights:
-- Loss after tax of GBP13.1m (2015: loss GBP12.7m) reflecting the business model, where the portfolio companies are largely subsidiaries developing their technologies and are therefore currently loss making
-- Available cash resources of GBP9.5m (at 31 December 2015: GBP23.2m). Cash used in operations, was GBP12.9 million (2015: GBP10.7 million)
Post year end highlights:
-- Vortex BioSciences
o Liquid biopsy VTX-1 commercially launched in 2017
-- Glycotest
o Peer review publication: "Changes in the glycosylation of kininogen and the development of a kininogen based algorithm for the early detection of HCC"
Commenting on the Group's 2016 full year results, Francois Martelet, CEO of NetScientific, said: "NetScientific is a strong healthcare IP commercialisation group with a world-class portfolio of disruptive technologies, led by experienced management teams.
"2016 was a year of execution, where we focused on delivering the individual development milestones within each of our portfolio companies, paving the way in 2017 for continued progress and maturation of our investments.
"We continue to believe that we have a world-class portfolio of companies, experienced and relevant management teams and the business and financing strategies to support their development and attract the necessary third-party validation capital."
Meeting and conference call for analysts
Francois Martelet, Chief Executive Officer, and Ian Postlethwaite, Chief Financial Officer, will hold a presentation and simultaneous conference call with Q&A for analysts today at 09:30 at Stifel's offices, 150 Cheapside, London, EC2V 6ET. Gene Walther, Chief Executive Officer of Vortex BioSciences, and Foad Dabiri, Chief Executive Officer of WANDA, will join via the conference call to give updates on the progress of their respective businesses. The presentation will be available on NetScientific's website shortly before the call at http://netscientific.net/investors/presentations.
Participant dial-in: 08006940257
International dial-in: +44 (0) 1452 555566
Participant code: 67358107
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800 François R. Martelet, M.D., CEO Ian Postlethwaite, CFO Stifel Nicolaus Europe Tel: +44 (0)20 7710 7600 Limited (NOMAD and broker) Jonathan Senior/ David Arch/ Ben Maddison Consilium Strategic Tel: +44 (0)20 3709 5700 Communications netscientific@consilium-comms.com Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Laura Thornton
About NetScientific
NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net
CHAIRMAN'S AND CHIEF EXECUTIVE OFFICER'S STATEMENT
NetScientific is a transatlantic healthcare IP commercialisation Group focused on sourcing, funding and commercialising technologies and companies that have the potential to treat chronic diseases and significantly improve the health and well-being of people.
The UK is the global hub for IP commercialisation with transatlantic businesses selecting the UK as listing destination due to the strength of the peer group and understanding of the sector. NetScientific is well placed amongst its peer group to benefit from the appreciation and understanding of this sector. The Group is highly international in its approach and differentiated by its global network and majority shareholding positions in its portfolio assets.
During 2016, the Group has continued to significantly progress its breakthrough technologies towards commercialisation, with portfolio assets across the Diagnostics, Therapeutics and Digital Health sectors.
Great progress has been achieved with the lead portfolio companies, which are either beginning, or poised for, commercialisation. Notably, Vortex Biosciences, which is developing a novel liquid biopsy technology that aims to revolutionise cancer diagnosis, monitoring and treatment by isolating and collecting intact circulating tumour cells, launched its first product, the VTX-1 instrument, at Tri-Conference on Molecular Medicine on 21 February 2017. NetScientific also made a further investment in PDS Biotechnology to help support the development of its novel and highly promising broad-based cancer immunotherapy, the Versamune(R) platform, which is about to commence multiple Phase II clinical programmes. ProAxsis, an early warning diagnostic test for infection in cystic fibrosis and COPD patients, gained a CE Mark for its ProteaseTag immunoassay, and is preparing to launch its point-of-care (POC) test, NEATstik(R), this year. Glycotest, a liver diagnostics company, completed a head-to-head clinical evaluation of its liver cancer panel which demonstrated significantly better results versus the current industry standard, with further development of commercial grade kits for CLIA laboratory use underway. Another important milestone in 2016 was Wanda's collaboration with Dignity Health, Inc. on Oncoverse, a virtual care and treatment plan for cancer patients. Dignity Health manages one of the largest healthcare systems in the US.
Vortex Biosciences
Vortex Biosciences gained a CE Mark approval for its VTX-1 instrument during the period, and VTX-1 was registered as a Class I medical Device with the FDA. Vortex published key results in the November 2016's edition of the journal, Oncotarget, showing that its next-generation circulating tumour cells (CTC) capture system helped enhance the clinical assessment of a cancer's mutation profile and metastatic status. Combining CTC capture and analysis, with separate and complementary evaluation of cfDNA (circulating free DNA), offers a better understanding of dynamic tumour profiles and a patient's disease. Both of these were significant milestones on the path towards making the VTX-1 instrument commercially available in early 2017 and generating sales into the clinical market in the US.
Wanda
Wanda, our lead digital health company, has developed an artificial intelligence (AI) platform for remote patient monitoring that enables care teams to help patients live longer, with more efficient and lower cost care. In 2016, significant efforts were made to establish contracts and patient user plans in the home care, nursing, direct-to-consumer and B2B segments. Initial client base results have demonstrated the power of Wanda's in-line predictive analytic capabilities in managing patients with chronic disease conditions.
Wanda has been able to agree a number of deals with clients across a broad cross-section of home healthcare providers, but has faced a number of commercial headwinds in determining the best route forward for optimal revenue and profit generation. During the previous 12 months, despite an upgraded product suite, the company has achieved only limited business traction and revenues in the market have been below expectations. This, in combination with the competitive, complex and fast-changing digital health commercial environment has made gaining momentum difficult. Based on a strategic review, we took the decision to restructure the Company to focus on its core capabilities. Foad Dabiri, Wanda's Chief Technology Officer, was recently promoted to Chief Executive Officer to lead Wanda based on his strong expertise in the digital health sector.
Also as a result of an in-house impairment review, we have taken a provision in these results on the debt provided to Wanda, reducing the outstanding debt from GBP8.8 million to GBP3.8 million. This has no impact at Group level, but is nevertheless significant at Company level.
OncoVerse is a digital health platform designed to enable cancer patients' care teams to collaborate in real-time to allow clinicians across all disciplines to work together to determine the most effective treatment plan for cancer patients. OncoVerse was initially conceived by a Dignity Health physician who wanted a tool to improve team collaboration, especially when evaluating a complex cancer case and determining the appropriate patient treatment plan. Dignity Health engaged Wanda to develop the software due to the Company's proven track record supporting informed treatment decisions and reducing administrative costs. The collaboration with Dignity Health is now well advanced and the concept attracts interest from major corporations.
PDS Biotechnology
PDS Biotechnology continued to see strong progress with its T-cell activating technology platform, Versamune(R), which combines three critical attributes for an effective immunotherapy: T-cell induction, reduced tumour suppression and priming of a potent anti-tumour response without the conventional associated toxicities. PDS's oncology pipeline includes compounds for prostate, ovarian, breast and colorectal cancers, in addition to its lead PDS0101 programme for several HPV-related cancers. PDS made some important advances through the year in progressing its lead Versamune(R) T-cell Activating platform, and presented results at a number of conferences (most recently PDS0101 Phase I/IIa data from a number of HPV-induced cancers at the Society for Immunotherapy of Cancer meeting in November 2016). A key event for the company was the meeting with the FDA in August 2016 regarding the design of the Phase II clinical studies in several HPV related cancers.
Glucosense
Glucosense, our smallest portfolio company and the focus of minimal investment in the period was dissolved after it had reached a go/no-go point and failed to replicate its initial in vitro results. The investment in Glucosense totalled only GBP0.7m in equity and loans.
Seed Portfolio
During the year, the company reviewed its portfolio of five seed stage investments (the 'Seed Portfolio'). The review concluded that there were no plans to invest additional funds in the Seed Portfolio because it was unlikely that NetScientific's investment criteria of gaining initial majority control would be achieved. Limited investment has been made to date, mostly in the form of convertible loans. Nevertheless, these investments are reviewed periodically in tandem with the companies' business plans and progress.
Conclusion
In summary, 2016 saw continued progress across most of the portfolio as the companies strengthen their individual positions working toward raising new funds. Additionally, NetScientific continues to evaluate new opportunities for investment, as it moves new technologies towards an eventual valuable exit in line with business strategy.
Finance
For the year, the Group made a loss of GBP13.1 million (2015: loss GBP12.7 million) which is split between continuing and discontinued operations as follows:
- Continuing operations GBP12.4 million (2015: GBP10.4 million) - Discontinued operations GBP0.7 million (2015: GBP2.3 million)
The loss reflects the business model, where the portfolio companies are largely subsidiaries developing their technologies and are therefore currently loss making.
Cash
Cash on the balance sheet as at 31 December 2016 was GBP9.5 million (2015: GBP23.2 million). Cash used in operations, was GBP12.9 million (2015: GBP10.7 million).
Going concern
The Directors have prepared and reviewed budget forecasts which were approved by the board of directors in the board meeting of March 2017. The budget considered amongst other things the timing of the Series A funding rounds of the subsidiary companies and the cash position of the Group at the beginning of 2017. After due consideration of these forecasts and current cash resources, the Directors consider that the Company and Group have adequate financial resources to continue in operational existence for the foreseeable future (being at least twelve months from the date of this report), and for this reason the financial statements have been prepared on a going concern basis.
Board changes
Peter Thoms stepped down as NetScientific Chief Financial Officer on 26th January 2016, and we thank him for his contribution to the Group.
On 17 February 2016, the Group was pleased to announce the appointment of Professor Stephen Smith as Non-Executive Director. Stephen has held senior leadership roles in the NHS and academia. He has had a long and distinguished career as a clinician scientist, Head of Department, Dean and CEO with the Medical Research Council, University of Cambridge, Imperial College, London and Imperial College Healthcare NHS Trust. During his career, Stephen has also spun out two companies from Cambridge University - Metris Therapeutics Ltd and GNI Group Ltd. GNI was established as a start up in Japan in 2001 and successfully achieved an Initial Public Offering (IPO) on the Tokyo Stock Exchange six years later.
On 15 June 2016, Ian Postlethwaite was appointed Chief Financial Officer of the Group. Ian had been the Finance Director of Allergy Therapeutics plc for 14 years and was a significant contributor to the success of the company. During that time, Allergy Therapeutics listed on AIM, achieved a number of financial goals, including two fund raisings in 2015 to support the Company's clinical and other development plans, and grew revenues from products on sale in Europe.
Summary and Outlook
In 2016, the NetScientific Group delivered on a number of development milestones critical to enhance the competitiveness and value of the individual portfolio companies. Whilst new pipeline opportunities will continue to be reviewed, the aim in 2017 is to focus on the growth of the Company on a number of levels, including further maturation of each lead portfolio Company's platform, including striking corporate deals in order to underline a coherent strategy and progression towards translation of technology success into commercial success. We continue to believe that we have a world-class portfolio of companies, experienced and relevant management teams and the business and financing strategies to support their development and attract the necessary third-party validation capital.
Hot Features
Premium
Sir Richard Sykes Francois R. Martelet,
M.D.
Non-Executive Director Chief Executive Officer
and Chairman
31 March 2017 31 March 2017
Consolidated Income Statement
For the year ended 31 December 2016
Notes 2016 2015
restated
GBP000's GBP000's
Continuing Operations
--------------------- -----------
Revenue 518 21
Cost of sales (255) (6)
--------------------- -----------
Gross profit 263 15
Other operating income 68 44
Research and development costs (7,443) (6,838)
General and administrative
costs (5,001) (2,843)
Other costs (316) (887)
Loss from operations (12,429) (10,509)
Finance income 94 77
Finance expense (8) -
Share of loss of associates (49) -
Loss before taxation (12,392) (10,432)
Income tax (charge)/credit (18) 12
--------------------- -----------
Loss for the year from continuing
operations (12,410) (10,420)
Discontinued Operations
--------------------- -----------
Loss for the year from discontinued
operations (666) (2,326)
--------------------- -----------
Total loss for the year (13,076) (12,746)
--------------------- -----------
Owners of the parent (11,195) (10,842)
Non-controlling interests (1,881) (1,904)
--------------------- -----------
(13,076) (12,746)
Basic and diluted loss per
share from continuing and
discontinued operations attributable
to owners of the parent during
the year: 4
Continuing operations (20.8p) (24.4p)
Discontinued operations (1.1p) (4.0p)
From loss for the year (21.9p) (28.4p)
--------------------- -----------
Consolidated Income Statement and Other Comprehensive Income
For the year ended 31 December 2016
2016 2015
GBP000's GBP000's
Loss for the year (13,076) (12,746)
Items that may be subsequently
reclassified to profit or
loss:
Exchange differences on translation
of foreign operations 634 134
Total comprehensive loss for
the year (12,442) (12,612)
---------------------- --------------------
Attributable to:
Owners of the parent (10,084) (10,596)
Non-controlling interests (2,358) (2,016)
--------- -----------
(12,442) (12,612)
--------- -----------
All other comprehensive income will be reclassified to retained earnings on the ultimate sale of any relevant subsidiary or investment company.
Consolidated Statement of Financial Position
As at 31 December 2016
Notes 2016 2015
GBP000's GBP000's
---------- ----------
Assets
Non-current assets
Property, plant and equipment 779 285
Investments in equity accounted 357 -
associates
Available for sale investments 6 2,863 1,807
Derivative financial assets 18 100
Other receivables 37 754
---------- ----------
Total non-current assets 4,054 2,946
---------- ----------
Current assets
Trade and other receivables 1,578 560
Cash and cash equivalents 9,456 23,239
---------- ----------
Total current assets 11,034 23,799
---------- ----------
Total assets 15,088 26,745
---------- ----------
Liabilities
Current liabilities
Trade and other payables (2,044) (2,156)
Loans and borrowings (128) (50)
---------- ----------
Total current liabilities (2,172) (2,206)
---------- ----------
Non-current liabilities
Loans and borrowings (80) -
Total non-current liabilities (80) -
---------- ----------
Total liabilities (2,252) (2,206)
---------- ----------
Net assets 12,836 24,539
---------- ----------
Issued capital and reserves
Attributable to the parent
Called up share capital 2,554 2,554
Share premium account 47,233 47,233
Capital reserve account 237 237
Foreign exchange reserve 1,802 691
Retained earnings (35,115) (24,371)
---------- ----------
Equity attributable to the
owners of the parent 16,711 26,344
Non-controlling interests (3,875) (1,805)
---------- ----------
Total equity 12,836 24,539
---------- ----------
Consolidated Statement of Changes in Equity
As at 31 December 2016
Shareholders' equity
---------- ---------- ---------- ---------- ------------------------------------
Foreign Non-
Share Share Capital Retained exchange controlling Total
capital premium reserve earnings reserve Total interests equity
GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's GBP000's
--------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -----------
1 January 2015 1,795 30,845 237 (13,529) 446 19,794 (1,098) 18,696
--------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -----------
Loss for the
year - - - (10,842) - (10,842) (1,904) (12,746)
--------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -----------
Other
comprehensive
income
Foreign
exchange
differences - - - - 245 245 (111) 134
Total
comprehensive
income - - - (10,842) 245 (10,597) (2,015) (12,612)
--------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -----------
Increase in
subsidiary
shareholding - - - (171) - (171) 220 49
Disposal of
subsidiaries - - - - - - 1,088 1,088
Issue of share
capital 759 17,450 - - - 18,209 - 18,209
Costs of share
issue - (1,062) - - - (1,062) - (1,062)
Share-based
payments - - - 171 - 171 - 171
--------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -----------
31 December
2015 2,554 47,233 237 (24,371) 691 26,344 (1,805) 24,539
--------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -----------
Loss for the
year - - - (11,195) - (11,195) (1,881) (13,076)
--------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -----------
Other
comprehensive
income
Foreign
exchange
differences - - - - 1,111 1,111 (477) 634
--------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -----------
Total
comprehensive
income - - - (11,195) 1,111 (10,084) (2,358) (12,442)
--------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -----------
Decrease in
subsidiary
shareholding - - - 39 - 39 (20) 19 Disposal of subsidiaries - - - 171 - 171 308 479 Share-based payments - - - 241 - 241 - 241 --------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ ----------- 31 December 2016 2,554 47,233 237 (35,115) 1,802 16,711 (3,875) 12,836 --------------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -----------
Consolidated Statement of Cash Flows
As at 31 December 2016
2016 2015
GBP000's GBP000's
---------- ----------
Cash flows from operating
activities
Loss after income tax including
discontinued operations (13,076) (12,746)
Adjustments for:
Depreciation of property,
plant and equipment 141 130
Amortisation of intangible
assets - 55
Loss on disposal of property,
plant and equipment (1) 3
Share of loss of associates
and joint venture 49 400
Gain on sale of associates
and joint venture - (214)
Loss on disposal of subsidiaries 483 508
Impairment of intangible
assets - 191
Provision against recoverability
of loan 75 177
Share-based payments 241 171
Bad debt written off - 4
Foreign exchange gains (121) (85)
Finance income (94) (77)
Finance costs 8 50
Tax charge 18 (108)
(12,277) (11,541)
Changes in working capital
Increase in trade and other
receivables (237) (55)
(Decrease)/Increase in trade
and other payables (364) 882
---------- ----------
Cash used in operations (12,878) (10,714)
---------- ----------
Income tax received 94 83
---------- ----------
Net cash used in operating
activities (12,784) (10,631)
---------- ----------
Cash flows from investing
activities
Investment in joint venture - (35)
Investment in associate (363) (25)
Proceeds from sale of associate - 25
Disposal of discontinued
subsidiaries, net of cash
disposed of - (108)
Purchase of property, plant
and equipment (470) (137)
Proceeds from sale of property,
plant and equipment 13 1
Purchase of intangible assets - (164)
Interest received 46 38
Purchase of available for (898) -
sale investments
Net cash used in investing
activities (1,672) (405)
---------- ----------
Cash flows from financing
activities
Proceeds from borrowings 50 50
Proceeds on change in subsidiary
shareholding 20 1
Proceeds from share issue - 18,208
Share issue cost - (1,062)
--------- ---------
Net cash from financing activities 70 17,197
--------- ---------
(Decrease) / increase in
cash and cash equivalents (14,386) 6,161
Cash and cash equivalents
at beginning of year 23,239 16,866
Exchange gains on cash and
cash equivalents 603 212
--------- ---------
Cash and cash equivalents
at end of year 9,456 23,239
--------- ---------
Notes to the Financial Information for the Year Ended 31 December 2016
1. GENERAL INFORMATION
The Company is a public limited company incorporated on 12 April 2012 and domiciled in England with registered number 08026888 and its shares are listed on the Alternative Investment Market (AIM) of the London Stock Exchange.
2. BASIS OF PREPARATION
The preliminary results of the year ended 31 December 2016 have been extracted from audited accounts which have not yet been delivered to the Registrar of Companies.
The Financial Information set out in this announcement do not constitute statutory accounts for the year ended 31 December 2016.
The report of the auditors on the statutory accounts for the year ended 31 December 2016 was unqualified and did not contain a statement under Section 498 of the Companies Act 2006. The Financial Statements for the year ended 31 December 2016 included in this announcement were authorised for issue in accordance with a resolution of the Board of Directors on 31 March 2017.
3. SIGNIFICANT ACCOUNTING POLICIES
The Group financial information has been prepared in accordance with International Financial Reporting Standards as adopted by the European Union that are effective for accounting periods beginning on or after 1 January 2016.
While the financial information included in this preliminary announcement has been prepared in accordance with IFRS, this announcement does not in itself contain sufficient information to comply with IFRS.
4. LOSS PER SHARE
The basic and diluted loss per share is calculated by dividing the loss for the financial year by the weighted average number of ordinary shares in issue during the year. Potential ordinary shares from outstanding options at 31 December 2016 of 3,412,324 (see note 26) are not treated as dilutive as the entity is loss making.
2016 2015
GBP000's GBP000's
------------------------------------- ----------- -----------
Loss attributable to equity holders
of the Company
Continuing operations 10,623 9,310
Discontinued operations 572 1,532
----------- -----------
Total 11,195 10,842
----------- -----------
Number of shares
Weighted average number of ordinary
shares in issue 51,075,695 38,228,552
-------------------------------------- ----------- -----------
5. INVESTMENTS IN SUBSIDIARY UNDERTAKINGS
The Group had the following subsidiaries at 31 December 2016:
Proportion Proportion
of ownership of ownership
Proportion Proportion interest interest
of of held by held by
ownership ownership non-controlling non-controlling
Country interest interest interests Interests
Primary of at 31 at 31 at 31 at 31
trading incorporation December December December December
Name address or registration 2016 2015 2016 2015
-------------------- --------- ----------------- ---------- ---------- ---------------- ----------------
NetScientific
UK Limited (a) UK 100% 100% - -
ProAxsis Ltd (b) UK 56.5% 56.5% 43.5% 43.5%
Glucosense
Diagnostics
Limited* (iv) (a) UK 60.7% 60.7% 39.3% 39.3%
Healthbox Israel
LLP (ii) (a) UK 50% 50% 50% 50%
IsraelScientific
Ltd (a) UK 100% 100% - -
NetScientific
America, Inc. (c) USA 100% 100% - -
Vortex BioSciences,
Inc. (i) (d) USA 95% 95% 5% 5%
Wanda, Inc.
(i)(iii) (e) USA 70.9% 71.3% 29.1% 28.7%
Glycotest,
Inc. (i) (f) USA 87.5% 87.5% 12.5% 12.5%
For all undertakings listed above, the country of operation is the same as its country of incorporation or registration.
All of the ownerships shown above relate to ordinary shareholdings.
(i) Options have been issued by Vortex BioSciences, Inc., Wanda, Inc. and Glycotest, Inc. which if exercised would dilute the Company's shareholding by 30%, 11% and 21% respectively.
(ii) The Group holds 50% of the voting shares and has the casting vote. The Group is entitled to 80% of profits subsequent to repayments of capital and member operational expenses.
(iii) Following issue of further shares during the year the Group's interest was reduced to 70.9% on 31 July 2016.
(iv) An application to strike-off Glucosense Diagnostics Limited was filed shortly after the year end.
6. AVAILABLE FOR SALE INVESTMENTS
Represent unquoted equity
securities
2016 2015
GBP000's GBP000's
--------------------------- ---------- ----------
At 1 January 1,807 1,807
Warrant exercised 100 -
Additions 956 -
At 31 December 2,863 1,807
---------------------------- ---------- ----------
Country of % of issued Currency
Name incorporation share capital denomination GBP000's
------------------ --------------- -------------- ------------- --------
PDS Biotechnology
Corporation USA 17.4% US$ 2,713
CytoVale, Inc. USA 2.15% US$ 150
Other -
------------------ --------------- -------------- ------------- --------
2,863
---------------------------------- -------------- ------------- --------
Valuation of unquoted equity investments
The fair value of unlisted securities is established using International Private Equity and Venture Capital Valuation Guidelines (IPEVCVG). Given the nature of the Group's investments in seed, start-up and early-stage companies, where there are often no current and no short-term future earnings or positive cash flows, it can be difficult to gauge the probability and financial impact of the success or failure of development or research activities and to make reliable cash flow forecasts.
The Group considers that fair value estimates that are based entirely on observable market data will be of greater reliability than those based on assumptions and accordingly where there has been any recent investment by third parties, the price of that investment will generally provide a basis of the valuation. Consequently, the most appropriate approach to determine fair value is a methodology that is based on market data, that being the price of a recent investment.
The length of period for which it remains appropriate to use the price of recent investment depends on the specific circumstances of the investment and the stability of the external environment. Where the Group considers that the price of recent investment, unadjusted, is no longer relevant and there are limited or no comparable companies or transactions from which to infer value, the Group carries out an enhanced assessment based on milestone analysis and/or industry and sector analysis. In applying the milestone analysis approach to investments in companies in early or development stages the Group seeks to determine whether there is an indication of change in fair value based on a consideration of performance against any milestones that were set at the time of the original investment decision, as well as taking into consideration the key market drivers of the investee company and the overall economic environment.
If there is no readily ascertainable value from following the 'price of recent investment' methodology, the Group considers alternative methodologies in the IPEVCVG guidelines, being principally discounted cash flows and price-earnings multiples requiring management to make assumptions over the timing and nature of future earnings and cash flows when calculating fair value. Factors which the Group considers include, inter alia, technical measures such as product development phases and patent approvals, financial measures such as cash burn rate and profitability expectations, and market and sales measures such as testing phases, product launches and market introduction.
Where a fair value cannot be estimated reliably, the investment is reported at the carrying value at the previous reporting date unless there is evidence that the investment has since been impaired.
At present, there is a significant range of possible fair value estimates and the probabilities of the various estimates cannot be reliably measured.
The investment includes a warrant with an identified fair value of GBP18k. This has been separately recognised.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR FLLLBDZFZBBQ
(END) Dow Jones Newswires
April 03, 2017 02:01 ET (06:01 GMT)
1 Year Netscientific Chart |
1 Month Netscientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
